### Doxorubicin

**Section:** 8. Immunomodulators and antineoplastics  >  8.2. Antineoplastics and supportive medicines  >  8.2.1. Cytotoxic medicines

**Essential medicine status:** ✔️

**ATC codes:** L01DB01

**Indication:** Hodgkin lymphoma

**ICD11 code:** 2C10.Z

**INN:** Doxorubicin

**Medicine type:** Chemical agent

**List type:** Complementary

**Formulations:**
- Parenteral > General injections > IV:
  - 10 mg in vial (hydrochloride)
  - 50 mg in vial (hydrochloride)
  - 2 mg per mL in 5 mL vial (hydrochloride)
  - 2 mg per mL in 25 mL vial (hydrochloride)

**EML status history:**
- First added in 2015 (TRS 994)
- Changed in 2023 (TRS 1049)

**Sex:** All

**Age:** Also recommended for children

**Therapeutic alternatives:**
- The recommendation is for this specific medicine

**Patent information:**
- Patents have expired in most jurisdictions
  - Read more about patents.

**Tags:** Cancer

**Wikipedia:** Doxorubicin

**DrugBank:** Doxorubicin

---

**Summary of evidence and Expert Committee recommendations**

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional dose forms of doxorubicin (2 mg/mL (hydrochloride) in 5 mL, 25 mL vial) to the EML and EMLc.

**Expert Committee report** 🗝️